The EASL Steatotic Liver Disease Summit 2027 is a three-day translational meeting that follows steatotic liver disease across its full continuum — from population policy to the patient in clinic, and from tissue microenvironment to the single stressed hepatocyte and its organelles. Across ten thematic sessions, three State-of-the-Art lectures, a dedicated best-abstract session, and eight ePoster sessions, the programme deliberately refuses to separate “basic” from “clinical.” The same disease spectrum — MASLD, MetALD and ALD, is interrogated at every scale by epidemiologists, hepatologists, pathologists, and cell and mechano-biologists.

The premise is that SLD is now a public-health problem with unresolved mechanistic and methodological foundations. The SLD Summit therefore pairs the field’s most pressing questions  (Has renaming the disease changed anything? Can a liver stiffness score predict outcomes? Can we still justify placebo arms?) with the biological and mechanistic insights that underpin these debates and will shape future answers. Designed for all stakeholders in the SLD community, from clinicians to translational and basic scientists, the SLD Summit provides a comprehensive update on the latest evidence, emerging data, and key developments across the field. It brings together both the policy headlines and the molecular mechanisms that drive them, reflecting the growing recognition that progress in SLD depends on understanding the connections between clinical practice, research, and biology.

The Summit covers steatotic liver disease across the entire metabolic–alcohol spectrum, spanning epidemiology and health policy, stigma and the patient voice, nutrition across the life course, diagnostics (histology, digital/AI pathology, elastography, fibrosis biomarkers), the cellular and microenvironmental mechanisms of progression, advanced/decompensated disease, clinical-trial methodology, and current and emerging therapeutics.

On completion, participants should be able to:

• Appraise the practical impact of the WHO resolution and the SLD nomenclature change on health systems, stigma and case-finding across specialties.
• Integrate multidisciplinary management of patients with SLD.
• Integrate nutritional assessment and intervention into SLD care across subtypes and generations, including AUD and adolescent populations.
• Critically evaluate diagnostic tools — biopsy, AI-assisted histology, 3D tissue mapping, vibration-controlled and shear-wave elastography, and serum fibrosis markers — for their real prognostic and monitoring value.
• Differentiate the cellular and microenvironmental mechanisms (macrophage niches, matrix stiffness, organelle crosstalk, hepatocyte heterogeneity, mitochondrial signaling) that drive SLD progression.
• Apply current management principles for advanced SLD, including portal hypertension, prevention of decompensation and re-compensation, and the role of bariatric surgery.
• Analyse the methodological challenges of MASH trials — placebo arms, screen failure, non-response — and interpret responder definitions.
• Summarise approved and pipeline therapies for MASH and ALD, and the complex problem of treating MetALD.

• To receive a comprehensive update on the latest scientific, clinical, and translational developments in Steatotic Liver Disease, including MASLD, MetALD, and ALD.
• To engage in thought-provoking discussions with international experts on the evolving landscape of SLD—from public health to precision diagnostics and emerging therapies.
• To present your research, gain valuable feedback, and connect with peers and mentors who can inspire your next career steps.
• To meet and learn from Key Opinion Leaders shaping the future of SLD research, clinical care, and policy worldwide.